UBT-251 vs Retatrutide
UBT-251 (written UBT251 in the trial literature) is an investigational once-weekly injectable triple agonist of the GLP-1, GIP and glucagon receptors, the same three-receptor class as retatrutide (phase 2 trial, PMID 42843337). Novo Nordisk licensed it outside Chinese mainland, Hong Kong, Macau and Taiwan in March 2025 (Novo Nordisk release). It is not the 'oral GLP-1 pill' circulating online. Its phase 2 obesity results appeared in Cell Metabolism on 7 October 2026: 24-week data that can't be read straight across to retatrutide's 48-week figure.
How It Works
Slows gastric emptying and blunts appetite, the same axis semaglutide and tirzepatide use to cut food intake.
Enhances glucose-dependent insulin secretion and is thought to improve the tolerability of the GLP-1 effect — the second arm shared with tirzepatide and retatrutide.
Raises energy expenditure and mobilises hepatic fat. Adding this third receptor is what separates a triple agonist like UBT-251 or retatrutide from a dual agonist.
UBT-251 is an injectable, not an oral pill, despite viral claims to the contrary. In the published phase 2 trial, participants received once-weekly subcutaneous doses of 2, 4 or 6 mg, stepped up from a lower starting dose (NCT07177469). Those are trial doses for an investigational drug, not a usable protocol.
What the Data Shows
UBT-251 now has peer-reviewed weight-loss data. In a randomized, double-blind, placebo-controlled phase 2 trial of 205 adults with overweight or obesity (without type 2 diabetes), mean body-weight change at week 24 ranged from −13.6% to −19.7% across four once-weekly dose arms, vs −2.0% on placebo; the most frequent adverse events were mild-to-moderate gastrointestinal symptoms (Cell Metabolism, PMID 42843337). What the viral posts skip: its 19.7% is a 24-week result, the comparators below ran 48 to 72 weeks, and none of these trials is head-to-head. Cross-trial bars show scale, not which drug is better.
Key Takeaways
- UBT-251 is a once-weekly subcutaneous triple agonist (GLP-1 / GIP / glucagon), the same receptor class as retatrutide, and an injection, not the 'oral pill' claimed online (PMIDs 42843337, 42712041).
- It is being developed by The United Bio-Technology (Hengqin), a wholly-owned subsidiary of The United Laboratories (TUL). Under a licence announced 24 March 2025, Novo Nordisk holds exclusive rights outside Chinese mainland, Hong Kong, Macau and Taiwan, where United Biotechnology keeps them (Novo Nordisk release).
- Phase 2 (205 adults, 24 weeks): mean weight change of −13.6% to −19.7% across dose arms vs −2.0% on placebo, with mild-to-moderate gastrointestinal symptoms the most frequent adverse events (PMID 42843337).
- Phase 1b (12 weeks, 1, 3 or 6 mg weekly): mean weight reduction of 8.96–13.48 kg vs a 1.57 kg gain on placebo (PMID 42712041).
- The established comparators (retatrutide, tirzepatide, semaglutide) all have peer-reviewed phase-2/3 weight-loss data (PMIDs 37366315, 35658024, 33567185). Retatrutide's headline 24.2% is a 48-week figure, so setting it against UBT-251's 24-week 19.7% compares different durations.
- How UBT-251 compares with retatrutide. None of the UBT251 trials registered on ClinicalTrials.gov (searched 9 October 2026) tests it against retatrutide, so every comparison so far is cross-trial, across different durations and populations.
- What happens beyond 24 weeks. Published data cover 12 to 24 weeks; long-term weight loss, weight regain after stopping, full safety and cardiometabolic outcomes are unknown. Phase 3 trials are registered (NCT07648225, NCT07659574) but have not reported.
- How the results hold up outside the developers. Both published trials include authors affiliated with the developer and with Novo Nordisk (PMIDs 42843337, 42712041).
- UBT-251 is investigational: not approved, not for sale, and not a substitute for any prescribed therapy.
Frequently Asked Questions
Is UBT-251 an oral GLP-1 pill?
No. UBT-251 is given as a once-weekly subcutaneous injection in its trials, and it is a triple agonist (GLP-1, GIP and glucagon) — not a GLP-1-only drug. The 'oral pill' framing circulating on social media is inaccurate.
Is UBT-251 better than retatrutide?
No one can say yet, because no head-to-head trial has been run. UBT-251's best published result is a 19.7% mean weight loss at 24 weeks in its phase 2 trial, while retatrutide's 24.2% is a 48-week phase 2 result. Different trials, durations and populations mean the viral '24% vs 19.7%' chart does not show which drug is stronger.
Who makes UBT-251?
It is being developed by The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), a wholly-owned subsidiary of The United Laboratories International Holdings (TUL). Under an exclusive licence announced on 24 March 2025, Novo Nordisk holds worldwide rights excluding Chinese mainland, Hong Kong, Macau and Taiwan, where United Biotechnology retains them.
How does UBT-251 work?
It activates three receptors at once — GLP-1 and GIP (appetite control and glucose-dependent insulin release) plus glucagon (increased energy expenditure and hepatic fat mobilisation). That is the same triple-agonist mechanism retatrutide uses.
Can I buy UBT-251?
No. UBT-251 is an investigational drug still in clinical trials, with phase 3 studies only now registered. It has no regulatory approval, so there is no legitimate retail source — anything marketed under that name should be treated as unverified.
🔬 General Research-Peptide Vendor
Not a source for UBT-251, which is investigational and has no legitimate retail source. Swiss Chems is HighPeptides' general vendor reference for the research peptides it does list.
Browse Swiss Chems →Affiliate links — support HighPeptides at no extra cost.
🛒 Recommended Products
General support items some people on a prescribed GLP-1-class medication keep on hand. There is no UBT-251 protocol: it is an investigational drug with no approved use.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
References
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → The Peptide Buyer’s Playbook — $19 All ebooks & guides →Educational purposes only. Not medical advice.
UBT-251 is an investigational compound in clinical trials, not approved by any regulator and not available for purchase.
UBT-251's efficacy figures on this page come from its published phase 1a/1b and phase 2 trials (12 and 24 weeks). The comparator figures (retatrutide, tirzepatide, semaglutide) come from separate trials of 48 to 72 weeks; none is head-to-head with UBT-251.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.